Cargando…
Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
AIMS: Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients with HF with mid‐range EF (HFmrEF). METHODS A...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083406/ https://www.ncbi.nlm.nih.gov/pubmed/31951680 http://dx.doi.org/10.1002/ehf2.12571 |
_version_ | 1783508526973321216 |
---|---|
author | Enzan, Nobuyuki Matsushima, Shouji Ide, Tomomi Kaku, Hidetaka Higo, Taiki Tsuchihashi‐Makaya, Miyuki Tsutsui, Hiroyuki |
author_facet | Enzan, Nobuyuki Matsushima, Shouji Ide, Tomomi Kaku, Hidetaka Higo, Taiki Tsuchihashi‐Makaya, Miyuki Tsutsui, Hiroyuki |
author_sort | Enzan, Nobuyuki |
collection | PubMed |
description | AIMS: Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients with HF with mid‐range EF (HFmrEF). METHODS AND RESULTS: We analysed HFmrEF (left ventricular EF 40–49%) patients enrolled in the Japanese Cardiac Registry of Heart Failure in Cardiology, which prospectively studied the clinical characteristics, treatments, and long‐term outcomes of patients hospitalized due to HF. Patients were divided into two groups according to the use of spironolactone at discharge. The primary outcome was a composite of all‐cause death or HF rehospitalization. A total of 457 patients had HFmrEF. The mean age was 69.3 years and 286 (62.6%) were male. Among them, spironolactone was prescribed at discharge in 158 patients (34.6%). Chronic kidney disease (7.6% vs. 16.8%, P = 0.007) was less prevalent and loop diuretics (89.2% vs. 70.2%, P < 0.001) were more often prescribed in patients with spironolactone. During a mean follow‐up of 2.2 years, patients with spironolactone had a lower incidence rate of the primary outcome than those without it (171.5 vs. 278.8 primary outcome per 1000 patient‐years, incidence rate ratio 0.61, 95% confidence interval 0.44–0.86; P = 0.004). After multivariable adjustment, spironolactone use at discharge was associated with a significant reduction in the composite of all‐cause death or HF rehospitalization (adjusted hazard ratio 0.63, 95% confidence interval 0.44–0.90, P = 0.010). CONCLUSIONS: Among patients with HF hospitalized for HFmrEF, spironolactone use at discharge was associated with better long‐term outcomes. |
format | Online Article Text |
id | pubmed-7083406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70834062020-03-24 Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction Enzan, Nobuyuki Matsushima, Shouji Ide, Tomomi Kaku, Hidetaka Higo, Taiki Tsuchihashi‐Makaya, Miyuki Tsutsui, Hiroyuki ESC Heart Fail Original Research Articles AIMS: Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients with HF with mid‐range EF (HFmrEF). METHODS AND RESULTS: We analysed HFmrEF (left ventricular EF 40–49%) patients enrolled in the Japanese Cardiac Registry of Heart Failure in Cardiology, which prospectively studied the clinical characteristics, treatments, and long‐term outcomes of patients hospitalized due to HF. Patients were divided into two groups according to the use of spironolactone at discharge. The primary outcome was a composite of all‐cause death or HF rehospitalization. A total of 457 patients had HFmrEF. The mean age was 69.3 years and 286 (62.6%) were male. Among them, spironolactone was prescribed at discharge in 158 patients (34.6%). Chronic kidney disease (7.6% vs. 16.8%, P = 0.007) was less prevalent and loop diuretics (89.2% vs. 70.2%, P < 0.001) were more often prescribed in patients with spironolactone. During a mean follow‐up of 2.2 years, patients with spironolactone had a lower incidence rate of the primary outcome than those without it (171.5 vs. 278.8 primary outcome per 1000 patient‐years, incidence rate ratio 0.61, 95% confidence interval 0.44–0.86; P = 0.004). After multivariable adjustment, spironolactone use at discharge was associated with a significant reduction in the composite of all‐cause death or HF rehospitalization (adjusted hazard ratio 0.63, 95% confidence interval 0.44–0.90, P = 0.010). CONCLUSIONS: Among patients with HF hospitalized for HFmrEF, spironolactone use at discharge was associated with better long‐term outcomes. John Wiley and Sons Inc. 2020-01-17 /pmc/articles/PMC7083406/ /pubmed/31951680 http://dx.doi.org/10.1002/ehf2.12571 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Articles Enzan, Nobuyuki Matsushima, Shouji Ide, Tomomi Kaku, Hidetaka Higo, Taiki Tsuchihashi‐Makaya, Miyuki Tsutsui, Hiroyuki Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
title | Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
title_full | Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
title_fullStr | Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
title_full_unstemmed | Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
title_short | Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
title_sort | spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083406/ https://www.ncbi.nlm.nih.gov/pubmed/31951680 http://dx.doi.org/10.1002/ehf2.12571 |
work_keys_str_mv | AT enzannobuyuki spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction AT matsushimashouji spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction AT idetomomi spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction AT kakuhidetaka spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction AT higotaiki spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction AT tsuchihashimakayamiyuki spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction AT tsutsuihiroyuki spironolactoneuseisassociatedwithimprovedoutcomesinheartfailurewithmidrangeejectionfraction |